- Editor's PickSeana Smith•2 days ago
Pfizer is buying Medivation for $14 billion. Medivation’s portfolio includes Xtandi, a treatment for prostate cancer that generates about $2 billion in worldwide annual sales. Valeant Pharmaceuticals (VRX) — Zoetis (ZTS) Chief Financial Officer Paul Herendeen has stepped down to become executive vice president of finance at Valeant and will take over the role of CFO from Robert Rosiello effective immediately.
- Barrons.com•9 hours ago
Schwartz focuses on general comments he’s hearing about spending on software-as-a-service offerings among companies, and also hiring trends at Workday: In aggregate, we detected a relatively good spending environment for SaaS products among our US- based channel checks (private SaaS companies, industry contacts, large systems integrators, etc.). Additionally, the management tone regarding business trends among public SaaS companies was uniformly strong, we assessed, at OPCO's Annual Technology Conference two weeks ago […] Hiring trends were seasonally stronger for Workday this 2Q. Workday's 2Q hiring trends showed seasonal improvements versus prior years, which we read through as a data point supporting our improving business/stock rebound thesis (see WDAY Jan. 28th report), and likely indicates that Workday is experiencing good pipeline expansion momentum and a favorable operating environment for new software sales.
Workday, Inc. (WDAY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||79.96 x 200|
|Ask||80.99 x 100|
|Day's Range||79.79 - 81.15|
|52wk Range||47.32 - 85.67|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-49.63|
|Avg Vol (3m)||1,588,331|
|Dividend & Yield||N/A (N/A)|